Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study-Reference-Cited by-同舟云学术

Evaluation of the Absolute Bioavailability of Pegylated Interferon Alfa-2a After Subcutaneous Administration to Healthy Male Volunteers: An Open-Label, Randomized, Parallel-Group Study

Published:2012-09 Issue:9 Volume:34 Page:1883-1891
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Brennan Barbara J.,Xu Zhi-Xin,Grippo Joseph F.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference26 articles.

1. An overview of emerging therapies for the treatment of chronic hepatitis C;Ilyas;Clin Liver Dis,2011

2. Boceprevir for previously treated chronic HCV genotype 1 infection;Bacon;N Engl J Med,2011

3. Response-guided telaprevir combination treatment for hepatitis C virus infection;Sherman;N Engl J Med,2011

4. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice;McHutchison;J Hepatol,2006

5. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus;Poynard;Lancet,1998

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type I IFN is siloed in endosomes;Proceedings of the National Academy of Sciences;2020-07-14

2. Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B;Expert Opinion on Drug Metabolism & Toxicology;2019-10-03

3. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B;Journal of Viral Hepatitis;2019-07

4. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C;British Journal of Clinical Pharmacology;2016-01-08

5. Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders;Liver International;2015-04-20